Tardive dyskinesia: what it is, causes, symptoms & treatment. Cleveland Clinic. Accessed 5 July 2023. https://my.clevelandclinic.org/health/articles/6125-tardive-dyskinesia

https://www.facebook.com/WebMD. What is tardive dyskinesia? WebMD. Accessed 5 July  2023. https://www.webmd.com/mental-health/tardive-dyskinesia

American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders. Fifth Edition. American Psychiatric Association. https://doi.org/10.1176/appi.books.9780890425596

Tardive dyskinesia. Mental Health America. Accessed 5 July 2023. https://mhanational.org/conditions/tardive-dyskinesia

Ricciardi L, Pringsheim T, Barnes TRE et al (2019) Treatment recommendations for tardive dyskinesia. Can J Psychiatry Rev Can Psychiatr 64(6):388–399. https://doi.org/10.1177/0706743719828968

Article  Google Scholar 

Mental illness. National Institute of Mental Health (NIMH). Accessed July 5, 2023. https://www.nimh.nih.gov/health/statistics/mental-illness

Keepers GA, Fochtmann LJ, Anzia JM et al (2020) The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 177(9):868–872. https://doi.org/10.1176/appi.ajp.2020.177901

Article  PubMed  Google Scholar 

Hutton B, Salanti G, Caldwell DM et al (2015) The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 162(11):777–784. https://doi.org/10.7326/M14-2385

Article  PubMed  Google Scholar 

Balduzzi S, Rücker G, Nikolakopoulou A et al (2023) netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. https://doi.org/10.18637/jss.v106.i02

Article  Google Scholar 

Hayashi T, Yokota N, Takahashi T et al (1997) Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study. Int Clin Psychopharmacol 12(4):199–205. https://doi.org/10.1097/00004850-199707000-00003

Article  CAS  PubMed  Google Scholar 

Glazer WM, Moore DC, Bowers MB, Bunney BS, Roffman M (1985) The treatment of tardive dyskinesia with baclofen. Psychopharmacology 87(4):480–483. https://doi.org/10.1007/BF00432517

Article  CAS  PubMed  Google Scholar 

Dabiri LM, Pasta D, Darby JK, Mosbacher D (1994) Effectiveness of vitamin E for treatment of long-term tardive dyskinesia. Am J Psychiatry 151(6):925–926. https://doi.org/10.1176/ajp.151.6.925

Article  CAS  PubMed  Google Scholar 

Correll CU, Cutler AJ, Kane JM, McEvoy JP, Liang GS, O’Brien CF (2018) Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. J Clin Psychiatry 80(1):18m12278. https://doi.org/10.4088/JCP.18m12278

Article  PubMed  Google Scholar 

Kojima T, Yamauchi T, Miyasaka M et al (1992) Treatment of tardive dyskinesia with ceruletide: a double-blind, placebo-controlled study. Psychiatry Res 43(2):129–136. https://doi.org/10.1016/0165-1781(92)90127-o

Article  CAS  PubMed  Google Scholar 

Adler LA, Rotrosen J, Edson R et al (1999) Vitamin E treatment for tardive dyskinesia. Veterans Affairs Cooperative Study #394 Study Group. Arch Gen Psychiatry 56(9):836–841. https://doi.org/10.1001/archpsyc.56.9.836

Article  CAS  PubMed  Google Scholar 

Goff DC, Renshaw PF, Sarid-Segal O, Dreyfuss DA, Amico ET, Ciraulo DA (1993) A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia. Biol Psychiatry 33(10):700–706. https://doi.org/10.1016/0006-3223(93)90119-x

Article  CAS  PubMed  Google Scholar 

Adler LA, Edson R, Lavori P et al (1998) Long-term treatment effects of vitamin E for tardive dyskinesia. Biol Psychiatry 43(12):868–872. https://doi.org/10.1016/s0006-3223(97)00027-9

Article  CAS  PubMed  Google Scholar 

Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen DC, Wu GY (2004) The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial. J Clin Psychopharmacol 24(1):83–86. https://doi.org/10.1097/01.jcp.0000104912.75206.2b

Article  CAS  PubMed  Google Scholar 

Mouret J, Khomais M, Lemoine P, Sebert P (1991) Low doses of insulin as a treatment of tardive dyskinesia: conjuncture or conjecture? Eur Neurol 31(4):199–203. https://doi.org/10.1159/000116678

Article  CAS  PubMed  Google Scholar 

Glazer WM, Naftolin F, Morgenstern H, Barnea ER, MacLusky NJ, Brenner LM (1985) Estrogen replacement and tardive dyskinesia. Psychoneuroendocrinology 10(3):345–350. https://doi.org/10.1016/0306-4530(85)90011-3

Article  CAS  PubMed  Google Scholar 

Ludatscher JI (1989) Stable remission of tardive dyskinesia by L-dopa. J Clin Psychopharmacol 9(1):39–41

Article  CAS  PubMed  Google Scholar 

de Montigny C, Chouinard G, Annable L (1979) Ineffectiveness of deanol in tardive dyskinesia: a placebo controlled study. Psychopharmacology 65(3):219–223. https://doi.org/10.1007/BF00492207

Article  PubMed  Google Scholar 

Castro F, Carrizo E, de Prieto Rincón D et al (2011) Effectiveness of melatonin in tardive dyskinesia. Invest Clin 52(3):252–260

PubMed  Google Scholar 

George J, Pridmore S, Aldous D (1981) Double blind controlled trial of deanol in tardive dyskinesia. Aust N Z J Psychiatry 15(1):68–71. https://doi.org/10.3109/00048678109159413

Article  CAS  PubMed  Google Scholar 

Glazer WM, Hafez H (1990) A comparison of masking effects of haloperidol versus molindone in tardive dyskinesia. Schizophr Res 3(5–6):315–320. https://doi.org/10.1016/0920-9964(90)90016-z

Article  CAS  PubMed  Google Scholar 

Matsunaga T, Ohyama S, Takehara S et al (1988) The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study. Prog Neuropsychopharmacol Biol Psychiatry 12(4):533–539. https://doi.org/10.1016/0278-5846(88)90112-1

Article  CAS  PubMed  Google Scholar 

Sommer BR, Cohen BM, Satlin A, Cole JO, Jandorf L, Dorsey F (1994) Changes in tardive dyskinesia symptoms in elderly patients treated with ganglioside GM1 or placebo. J Geriatr Psychiatry Neurol 7(4):234–237. https://doi.org/10.1177/089198879400700408

Article  CAS  PubMed  Google Scholar 

Hajioff J, Wallace M (1983) Effect of Co-dergocrine mesylate on tardive dyskinesia. A preliminary report Psychopharmacology (Berl) 79(1):1–3. https://doi.org/10.1007/BF00433006

Article  CAS  PubMed  Google Scholar 

Soni SD, Freeman HL, Bamrah JS, Sampath G (1986) Oxypertine in tardive dyskinesia: a long-term controlled study. Acta Psychiatr Scand 74(5):446–450. https://doi.org/10.1111/j.1600-0447.1986.tb06267.x

Article  CAS  PubMed  Google Scholar 

Soni SD, Freeman HL, Hussein EM (1984) Oxypertine in tardive dyskinesia: an 8-week controlled study. Br J Psychiatry J Ment Sci 144:48–52. https://doi.org/10.1192/bjp.144.1.48

Article  CAS  Google Scholar 

Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J (1986) Essential fatty acid supplementation in tardive dyskinesia. Am J Psychiatry 143(7):912–914. https://doi.org/10.1176/ajp.143.7.912

Article  CAS  PubMed  Google Scholar 

O’Brien CF, Jimenez R, Hauser RA et al (2015) NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord Off J Mov Disord Soc 30(12):1681–1687. https://doi.org/10.1002/mds.26330

Article  CAS  Google Scholar 

Simpson GM, Yadalam KG, Stephanos MJ (1988) Double-blind carbidopa/levodopa and placebo study in tardive dyskinesia. J Clin Psychopharmacol 8(4 Suppl):49S-51S

CAS  PubMed  Google Scholar 

Fisk GG, York SM (1987) The effect of sodium valproate on tardive dyskinesia–re